A. Delacrétaz

发表

Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers

C. Eap, A. von Gunten, P. Conus, 2016, Pharmacogenetics and genomics.

Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort

C. Eap, A. von Gunten, K. Plessen, 2022, BMC Psychiatry.

Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression.

M. Preisig, B. Penninx, G. Willemsen, 2016, Journal of affective disorders.

Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in Early Psychosis patients treated with psychotropic medication

K. Do, C. Eap, P. Conus, 2020, PloS one.

Evaluation of Cardiometabolic Risk in a Large Psychiatric Cohort and Comparison With a Population-Based Sample in Switzerland.

M. Preisig, P. Vollenweider, C. Eap, 2020, The Journal of clinical psychiatry.

Valproate is associated with early decrease of high‐density lipoprotein cholesterol levels in the psychiatric population

C. Eap, A. von Gunten, P. Conus, 2021, Basic & clinical pharmacology & toxicology.

Association of genetic risk scores with body mass index in Swiss psychiatric cohorts

Z. Kutalik, C. Eap, A. von Gunten, 2016, Pharmacogenetics and genomics.

Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia.

C. Eap, A. von Gunten, J. Aubry, 2017, Journal of clinical lipidology.

PHARMACOGENETIC AND CLINICAL STUDY ON METABOLIC SIDE EFFECTS INDUCED BY PSYCHOTROPIC DRUGS: FOCUS ON WEIGHT GAIN AND ON LIPID DISTURBANCES

A. Delacrétaz, 2017 .

Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments

Z. Kutalik, P. Magistretti, M. Preisig, 2015, Journal of clinical psychopharmacology.

Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs.

L. Applegate, C. Eap, A. von Gunten, 2017, Gene.

Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients

C. Eap, A. von Gunten, P. Conus, 2019, Clinical Epigenetics.

Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs

C. Eap, A. von Gunten, P. Conus, 2017, Pharmacogenetics and genomics.

Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances

M. Bochud, I. Guessous, C. Eap, 2018, Front. Psychiatry.

Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments

Z. Kutalik, P. Magistretti, M. Preisig, 2015, Pharmacogenetics and genomics.

Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses

C. Eap, A. von Gunten, P. Conus, 2019, Clinical Pharmacokinetics.

Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.

C. Eap, A. von Gunten, P. Conus, 2015, The Journal of clinical psychiatry.

Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort

Z. Kutalik, C. Correll, C. Eap, 2021, Translational Psychiatry.

Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysis

Z. Kutalik, C. Eap, A. von Gunten, 2023, Molecular Psychiatry.

Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression

Z. Kutalik, P. Magistretti, M. Preisig, 2015, PloS one.

Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric Cohort

M. Bochud, C. Eap, A. von Gunten, 2021, Frontiers in Psychiatry.

Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients

C. Eap, A. von Gunten, P. Conus, 2019, Clinical Epigenetics.

Association of genetic risk scores with body mass index in Swiss psychiatric cohorts

Z. Kutalik, C. Eap, L. Quteineh, 2016, Pharmacogenetics and genomics.

Amisulpride

P. Conus, C. Csajka, M. Guidi, 2019, Reactions Weekly.

DNA methylation may partly explain psychotropic drug-induced metabolic side effects: results from a prospective 1-month observational study

Z. Kutalik, M. Piras, C. Grosu, 2024, Clinical epigenetics.